TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04749459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChapStick Moisturizer, Strawberry Flavor
Description: A single topical application of ChapStick Moisturizer, Strawberry Flavor will be applied to the appropriate 40 square centimeter (cm\^2) test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 milligram per centimeter square (mg/cm\^2), using 80 +/-2 milligrams (mg) of material.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChapStick Moisturizer, Classic Flavor
Description: A single topical application of ChapStick Moisturizer, Classic Flavor will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISO 24444:2010 P2 Standard Reference Sunscreen
Description: A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
Study: NCT05152550

Intervention type: OTHER
Intervention: Non-severe pre-eclampsia
Description: Cases diagnosed as Non-severe pre-eclampsia after exclusion of severity features.
Study: NCT05968573

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Format with Captions
Description: A video with captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Format without Captions
Description: A video without captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Educator
Description: The video created by the research will be compared to a healthcare provider in terms of effectiveness in getting patients screened for HIV/HCV.
Study: NCT05319639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Leucovorin
Description: Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered on day 1 of each cycle at 45mg/m2 at dose level 1; 67.5 mg/m2 at dose level 2 ; 90 mg/m2 at dose level 3; 112.5 mg/m2 at dose level 4 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 at dose level 1; 150 mg/m2 at dose level 2 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
Study: NCT04833283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)
Description: Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ReOxy Cardio device
Description: Perform 4 trainings daily of intermittent hypoxic-hyperoxic trainings before surgery, using 40 min trainings periods, whereas moistened air will be delivered through a mask under constant monitoring of heart rate (HR) and SpO2.
Study: NCT06772532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906 - Formulation A
Description: Formulation A
Study: NCT05800249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PE0116
Description: This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
Study: NCT05875675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Pioglitazone Oral Tablet
Description: Dietary Supplement: Pioglitazone 30 mg by mouth daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary: Supplement: Placebo
Study: NCT05461950

Intervention type: PROCEDURE
Intervention: Extrauterine placental transfusion and physiology-based umbilical cord clamping
Description: Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room, the umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infants is breathing regularly (within 10 minutes after delivery)

Intervention type: PROCEDURE
Intervention: Extrauterine placental transfusion, intact cord stabilisation and physiology-based umbilical cord clamping
Description: Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room and necessary respiratory support is initiated (CPAP or PPV) by a neonatal team. The umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infant is breathing regularly with or without support (at maximum 10 minutes after delivery)

Intervention type: PROCEDURE
Intervention: Delayed umbilical cord clamping
Description: Umbilical cord is clamped and cut minimum 60 seconds after delivery to facilitate placental transfusion. Placenta is delivered after cord clamping. Infants needing respiratory support or other stabilisation are transferred to a warmer in the adjacent room where a neonatal team is waiting.
Study: NCT06310980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartpen
Description: use of a smartpen connected with glucose sensor by an digital application
Study: NCT06772532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906 - Formulation B
Description: Formulation B
Study: NCT06096558

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 5 mg Melatonin in one tablet, 30 minutes before night sleep

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet of placebo (starch)
Study: NCT06115187

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve ultrasound
Description: Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction studies
Description: Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
Study: NCT05284760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.
Study: NCT06772532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906 - Formulation B
Description: Formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906 - Formulation B
Description: Formulation B
Study: NCT05284760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.
Study: NCT04992520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 53G
Description: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 53G
Description: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a 2457T
Description: Shigella flexneri strain 2457T (Lot 1617) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a 2457T
Description: Shigella flexneri strain 2457T (Lot 1617) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.
Study: NCT05828693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SysLife©
Description: Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SysLife©, as intervention after closing the RCT-design
Description: Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.
Study: NCT04732741

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary Gamma-synuclein
Description: Gamma-synuclein salivary levels measured using ELISA assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary Gamma-synuclein
Description: Gamma-synuclein salivary levels measured using ELISA assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary Gamma-synuclein
Description: Gamma-synuclein salivary levels measured using ELISA assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Incisional biopsy
Description: A) Biopsy (reference standard): biopsy for group 1 will be performed by specialists in the national cancer institute.~B) Biopsy for oral potentially malignant lesions will be performed by the candidate from the most representative region.

Intervention type: DIAGNOSTIC_TEST
Intervention: Incisional biopsy
Description: A) Biopsy (reference standard): biopsy for group 1 will be performed by specialists in the national cancer institute.~B) Biopsy for oral potentially malignant lesions will be performed by the candidate from the most representative region.

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional visual and tactile examination
Description: Conventional visual and tactile examination using light and mirror

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional visual and tactile examination
Description: Conventional visual and tactile examination using light and mirror

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional visual and tactile examination
Description: Conventional visual and tactile examination using light and mirror
Study: NCT05997641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF-003
Description: Oral administration by capsules (1 mg, 5 mg, or 25 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF-003
Description: Oral administration by capsules (1 mg, 5 mg, or 25 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually matching 0 mg DF-003 capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually matching 0 mg DF-003 capsules.
Study: NCT05409261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Recombinant vaccine, contains Adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein
Study: NCT06479655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intravenous fentanyl infusion with dilution of 10mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intravenous morphine infusion with dilution 1mg/ml
Study: NCT06772532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906 - Formulation C
Description: Formulation C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906 - Formulation C
Description: Formulation C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906 - Formulation C
Description: Formulation C
Study: NCT06771128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba oral tablet
Description: patients receive Ginkgo Biloba oral tablet 120 mg once daily
Study: NCT06493955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity for 12 months
Description: 6 additional months of adapted physical activity after the 6 first months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted physical activity for 6 months
Description: standard 6-month prescription for adapted physical activity
Study: NCT04925609

Intervention type: DRUG
Group type: OTHER
Intervention: Brigatinib
Description: Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.

Intervention type: DRUG
Group type: OTHER
Intervention: Brigatinib
Description: Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
Study: NCT05616260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide tablet (encapsulated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide tablet (encapsulated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar capsule manufactured to match encapsulated Acetazolamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar capsule manufactured to match encapsulated Acetazolamide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Standard CPAP device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Standard CPAP device
Study: NCT05095207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150 mg orally daily, day 1 to 28.
Study: NCT06164379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
Study: NCT06542055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative pulmonary rehabilitation exercise
Description: Besides receiving preoperative thoracic surgery health education manuals and postoperative regular pulmonary rehabilitation exercises, they also receive exercises originally tailored for pulmonary rehabilitation, including upper-body resistance exercise, lower-body resistance exercise, aerobic exercise, and respiratory muscle training for 4-7 days before surgery. In addition, a communication app group will be set up and an exercise diary will be provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative education and postoperative exercise
Description: Receiving preoperative thoracic surgery health education manual and postoperative regular pulmonary rehabilitation exercises
Study: NCT05986526

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation without posterior wall ablation
Description: Pulmonary vein isolation with Pulsed field ablation without left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation with posterior wall ablation
Description: Pulmonary vein isolation with Pulsed field ablation with left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
Study: NCT04558814

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum galectin-9 level
Description: Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum galectin-9 level
Description: Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group
Study: NCT06221475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088 coated tablet 10 mg
Description: 4 coated tablets (10 mg) per single dose 30 min after a light meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BAY2927088 solution for infusion
Description: IV infusion 15 min ending at 2 hours oral post-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BAY2927088 oral solution
Description: After a light meal
Study: NCT05915442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: 100mg IV once every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: 150 mg orally (PO) once a day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: 240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Standard of care metastasis-directed hypofractionated radiotherapy treatment starting 4 weeks (+/- 1 week) of starting Etrumadenant and Quemliclustat
Study: NCT04940910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black rice bran extract
Description: 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
Study: NCT05190003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Study
Description: On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises.